First AD

Second AD

Reflections on Plozasiran Trial Data and Future Potential

Video content above is prompted by the following:

What other approaches have been tested or are in development for treating familial chylomicronemia syndrome (FCS)?

How can clinicians integrate emerging therapy advancements into their clinical practice for the management of FCS? What strategies should be adopted to stay updated with ongoing research and treatment options?

Emerging RNAi-Based Therapies for FCS, Dyslipidemia

 Peers & Perspective page is a resource for sit-down video interviews between expert colleagues and peers on major topics in clinical practice and research.

Peers & Perspectives

Familial chylomicronemia syndrome (FCS) treatment advancements include gene therapies, antisense oligonucleotides, and RNA interference technologies. These approaches aim to reduce triglyceride levels and manage symptoms more effectively. Clinicians can integrate these emerging therapies by staying informed through continuous education, attending relevant conferences, and collaborating with specialists. Developing a multidisciplinary approach and leveraging digital platforms for real-time updates are crucial strategies. Engaging in clinical trials and fostering patient-centered care will also enhance the management of FCS, ensuring that patients receive the most current and effective treatments.

Panelists discuss how various new and developing approaches for treating familial chylomicronemia syndrome are emerging, and emphasize the importance for clinicians to integrate these advancements into practice while staying current with ongoing research and evolving treatment strategies.

Novel Research Frontiers on the Management of FCS